首页
订购/客服:400-666-5481

Altiratinib

    
10mM in DMSO

Altiratinib

源叶(MedMol)
T93277 一键复制产品信息
1345847-93-9
C26H21F3N4O4
510.46
DCC-27011;N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
货号 规格 价格 上海 北京 珠海 重庆 武汉 购买数量
T93277-1ml
10mM in DMSO

¥602.00

10 - - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品
产品描述: VEGFR2 选择性抑制剂;VEGFR2 Selective Inhibitors;;InformationAltiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor ofTRK, Met (c-Met), TIE2, and VEGFR2 kinaseswith IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. It inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM.TargetsMET Y1230C (Cell-free assay); TrkA (Cell-free assay); TrkC (Cell-free assay); MET Y1230C (Cell-free assay); MET D1228N (Cell-free assay) 31650,0.37 nM; 0.85 nM; 0.85 nM; 1.2 nM; 1.3 nMIn vitroAltiratinib is >10-fold selective for MET versus FMS and KIT, and >50-fold selective for MET versus ABL1, FYN, HER1 (EGFR), p38α (MAPK14), PDGFRα, PDGFRβ, RET, and SRC. Altiratinib exhibits IC50s of 0.69 nmol/L in K562 cells, 1.2 nmol/L in SK-N-SH cells for inhibition of NGF-stimulated TRKA phosphorylation. Altiratinib inhibits constitutive TRKA phosphorylation with an IC50 of 1.4 nmol/L in KM-12 cells. Altiratinib inhibits HGF-stimulated MET phosphorylation in HUVECs, exhibiting an IC50 of 2.3 nmol/L. In ANG1-stimulated HUVECs and EA.hy926 cells, altiratinib exhibits IC50 values of 1.0 nmol/L and 2.6 nmol/L, respectively, for inhibition of TIE2 phosphorylation. In VEGF-stimulated HUVECs, altiratinib inhibits VEGFR2 phosphorylation with an IC50 of 4.7 nmol/L. Altiratinib potently inhibits cellular proliferation in MET-amplified EBC-1 and MKN-45 cells, as well as TPM3-TRKA fusion KM-12 cells, but only weakly inhibits other cancer cell lines, including proliferation of M-NFS-60 (IC50, 770 nmol/L); A375, BT-474, HCT-116, PC-3, SK-MEL-28, U87, and A549 cells (IC50s > 1,000 nmol/L).Cell Research(from reference)Cell lines:EBC-1, M-NFS-60, SK-MEL-28, MKN-45, MV-4-11, A375, HCT-116, BT-474, KM-12, PC-3, and U-87-MG cells Incubation Time:72 h 
体内研究: 单次口服 30 mg/kg Altiratinib,可在整个 24 小时内抑制 95% 以上的 MET 磷酸化。单次口服 10 mg/kg Altiratinib,可在 12 小时内完全抑制 MET 磷酸化,并在给药后 24 小时内抑制73%。每日两次,每次 10 mg/kg 的 Altiratinib 可导致 BLI 信号显著降低90%。Altiratinib 具有口服给药的特性,并具有很强的血脑屏障穿透性,这对于最终治疗脑癌和脑转移瘤具有重要意义。
保存条件: -80℃(运输条件:冰袋低温运输)
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 1.959 ml 9.795 ml 19.59 ml
5 mM 0.392 ml 1.959 ml 3.918 ml
10 mM 0.196 ml 0.98 ml 1.959 ml
50 mM 0.039 ml 0.196 ml 0.392 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×